Puget Sound Blood Center

Bioverativ Therapeutics Inc.

Seattle Genetics, Inc.

Bristol-myers Squibb Compnay

Seagen Inc.

Neil Josephson

Haiyan Jiang

Glenn Pierce

Tongyao Liu

Sriram Krishnamoorthy

Benedetto Farsaci

Anthony Cao

Ryan Heiser

Thomas Manley

Pierce Glenn

The present disclosure provides methods of administering chimeric and hybrid Factor VIII (FVIII) polypeptides comprising FVIII and Fc to subjects at risk of developing inhibitory FVIII immune responses, including anti-FVIII antibodies and/or cell-mediated immunity. The administration is sufficient to promote coagulation and to induce immune tolerance to FVIII. The chimeric polypeptide can comprise full-length FVIII or a FVIII polypeptide containing a deletion, e.g., a full or partial deletion of the B domain.

Methods of reducing immunogenicity against factor VIII in individuals undergoing factor VIII therapy

The present disclosure, relates, in general to methods for improving adverse events in subjects receiving treatment with an anti-CD30 antibody drug conjugate, optionally also receiving accompanying chemotherapy. Adverse events include peripheral neuropathy and neutropenia.

Methods of reducing side effects of anti-CD30 antibody drug conjugate therapy

This disclosure provides methods for treating a tumor in a subject comprising administering to the subject an anti-PD-1 antibody and an anti-CD30 antibody. In some embodiments, the tumor is derived from a lymphoma (e.g., a Hodgkin lymphoma or a non-Hodgkin lymphoma). In certain embodiments, the anti-CD30 antibody is an antibody-drug conjugate, e.g., brentuximab vedotin.

Use of an anti-PD-1 antibody in combination with an anti-CD30 antibody in cancer treatment

This invention relates to methods and compositions for suppressing an immune response to Factor VIII in subjects suffering from hemophilia A and having preformed inhibitor antibodies against Factor VIII, and compositions and methods that advantageously render subjects amenable to standard treatments for hemophilia A, including Factor VIII replacement therapy.

Suppression of immune response to factor VIII in hemophilia A patients

Growing community of inventors

Seattle, WA, United States of America

Neil Josephson